SEC Form 4Coverage since Jun 1, 2026
$MAIA insider trading
Over the last 12 months, MAIA Biotechnology insiders reported 3 buys totaling $204K and no sales across SEC Form 4 filings.
- Bought · 12m
- $204K 3 events
- Sold · 12m
- — 0 events
- Events · 12m
- 3 Form 4 filings, grouped
- Insiders · 12m
- 3 distinct reporters
- 10b5-1 share
- 0% pre-arranged plans
Side
Price · $MAIA · 12Mvia TradingView
Top insiders · 12m
Vitoc VladChief Executive Officer1× · $101K
Smith Stan—1× · $100K
Gryaznov SergeiChief Scientific Officer1× · $3K
All insider trades
3 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | Vitoc VladChief Executive Officer · O·D·10% | ▲ Buy | 72,700 | $1.39 | $101K | +8% | — |
| Jun 1, 2026 | Smith StanD | ▲ Buy | 75,000 | $1.34 | $100K | +5.2% | indirect |
| Jun 1, 2026 | Gryaznov SergeiChief Scientific Officer · O | ▲ Buy | 2,000 | $1.34 | $3K | +4.5% | — |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $MAIA feed.